Lactylation‐Driven IGF2BP3‐Mediated Serine Metabolism Reprogramming and RNA m6A—Modification Promotes Lenvatinib Resistance in HCC. The gene discussed is IGF2BP3; the disease is hepatocellular carcinoma.